Virinchi Limited has completed the allotment of 74,00,000 convertible equity warrants to Vivo Bio Tech Limited, a promoter group entity, marking a significant capital raising initiative. The allotment was approved by the company's Stakeholders Relationship Committee on January 9, 2026, following comprehensive regulatory approvals and shareholder consent.

Warrant Allotment Details

The convertible equity warrants were issued at a price of ₹28.00 per warrant, comprising a face value of ₹10.00 and a premium of ₹18.00. The company has received ₹5.18 crores as the initial 25% subscription amount from the allottee.

Regulatory Approvals and Framework

The warrant issuance was conducted under a comprehensive regulatory framework with multiple approvals. Shareholders had initially approved the issuance of up to 2,00,00,000 convertible equity warrants through a special resolution passed at an Extra-Ordinary General Meeting held on November 15, 2025. The company subsequently received in-principle approvals from both BSE (letter LOD/PREF/KS/FIP/1456/2025-26 dated December 31, 2025) and NSE (letter NSE/LIST/51564 dated December 31, 2025).

The allotment was executed on a preferential basis in accordance with SEBI (ICDR) Regulations, 2018, ensuring compliance with all regulatory requirements for such capital market transactions.

Conversion Terms and Timeline

The convertible warrants carry specific terms for conversion into equity shares. Each warrant is convertible into one fully paid-up equity share of face value ₹10.00 upon payment of the remaining 75% of the issue price, which amounts to ₹21.00 per warrant. The warrants must be exercised within 18 months from the allotment date, and warrant holders can exercise their conversion rights in one or more tranches during this period.

If warrants remain unexercised beyond the 18-month tenure, they will lapse automatically, and the amounts paid by warrant holders will be forfeited by the company.

Impact on Shareholding Pattern

The warrant allotment will significantly alter Virinchi Limited's shareholding structure upon full conversion. The analysis assumes complete conversion of the allotted warrants into equity shares.

The conversion will increase the promoter group's stake by 4.20 percentage points while correspondingly reducing public shareholding. Currently, there is no change in the company's paid-up share capital as the warrants represent a contingent allotment pending full payment and conversion.

Financial Implications

Upon full conversion, Virinchi Limited will receive a total consideration of ₹20.72 crores from the warrant exercise. The company has already collected ₹5.18 crores as the initial payment, with the remaining ₹15.54 crores expected upon warrant conversion. This capital infusion will strengthen the company's financial position and provide resources for business expansion and operational requirements.

The preferential allotment to a promoter group entity demonstrates confidence in the company's prospects while ensuring that the additional capital comes from committed long-term stakeholders aligned with the company's strategic objectives.

Virinchi Limited , a leading technology solutions provider, has successfully executed the first phase of its Rs 56.00 crore fundraising initiative. The company has allotted 40 lakh convertible equity warrants to IT Peer Technologies LLC at Rs 28.00 per warrant, following regulatory approvals and shareholder consent.

Warrant Allotment Details

The Stakeholders Relationship Committee approved the allotment on January 07, 2026, following in-principle approvals from both BSE and NSE received on December 31, 2025. The allotment represents the first tranche of the company's broader fundraising plan.

Complete Fundraising Framework

The overall fundraising plan, approved by shareholders at the Extraordinary General Meeting held on November 15, 2025, encompasses a larger scope:

Impact on Shareholding Structure

The current allotment has modified the company's shareholding pattern, with further changes expected upon full conversion:

Conversion Terms and Timeline

The warrants carry specific conversion provisions designed to provide flexibility to warrant holders:

• Conversion Ratio: Each warrant convertible into 1 equity share
• Exercise Period: Within 18 months from allotment date
• Payment Structure: 25% paid upfront (Rs 7.00 per warrant), balance 75% (Rs 21.00 per warrant) upon conversion
• Flexibility: Rights exercisable in one or more tranches
• Forfeiture Clause: Unexercised warrants will lapse after 18 months with forfeiture of paid amount

Regulatory Compliance and Next Steps

The allotment follows full regulatory compliance under SEBI (ICDR) Regulations, 2018, and SEBI Listing Regulations. The company received necessary approvals from both stock exchanges, confirming adherence to preferential issue norms.

The remaining portion of the fundraising plan involves allotment to promoter group entity Vivo Bio Tech Limited, which is expected to significantly increase promoter shareholding from the current 37.51% to 44.44% upon full conversion of all approved warrants.

This strategic fundraising initiative positions Virinchi to strengthen its financial foundation and support future growth initiatives in the technology solutions sector.